Key Highlights

● Merck KGaA plans to acquire the company for $20.00 in cash per ADS.

● The deal is valued at about $1.3 billion in Equity terms.

● Closing is expected in the first quarter of 2027.

● Holders representing about 14% of voting power signed support agreements.

Silence Therapeutics plc (NASDAQ:SLN) has moved from an independent siRNA developer to a company working through the closing steps of a sale. Under an agreement dated Oct. 18, 2026, Merck KGaA, Darmstadt, Germany, plans to acquire Silence for $20.00 in cash per American depositary share, a deal valued at about $1.3 billion in equity terms. With the transaction structured as a UK scheme of arrangement, attention now turns less to clinical news and more to the approvals, votes and court steps that may decide whether, and when, holders receive that cash.

Latest Company Context

The company's Form 10-Q for the quarter ended Sept. 30, 2026, describes the transaction as a court-sanctioned scheme under Part 26 of the UK Companies Act 2006, with $6.6667 in cash payable per ordinary share and each ADS representing three ordinary shares. Silence expects the deal to close in the first quarter of 2027, and the agreement carries an end date of April 30, 2027, subject to a short automatic extension in certain cases.

There is no financing condition. Holders representing about 14% of voting power have signed voting and support agreements. Financially, Silence reported no Revenue in the third quarter and a net loss of $12.4 million, narrower than the $21.0 million loss a year earlier. Cash and equivalents stood at $247.7 million at Sept. 30, lifted by an August offering of ADSs at $13.50 that raised $201.3 million in gross proceeds.

Key Business and index Drivers

The asset at the center of the deal is divesiran, a quarterly-dosed siRNA therapy for polycythemia vera. In the Phase 2 SANRECO study of 48 phlebotomy-dependent patients, reported in August 2026, divesiran achieved an 88% responder rate versus 19% for placebo, and mean phlebotomies over weeks 0 to 36 fell to 0.2 versus 2.1. The program holds U.S. Fast Track and Orphan Drug designations and European orphan designation.

In a public post filed with the SEC, Silence said Merck has the scale and commercial capabilities to accelerate divesiran's Phase 3 development, and that its other siRNA programs would sit within Merck Healthcare. Zerlasiran, a Phase 3-ready Lp(a)-lowering candidate, was described in the 10-Q as positioned for a potential third-party partner. Existing collaboration ties, including a research Partnership with AstraZeneca carrying $55.2 million of contract liabilities at Sept. 30, may also Factor into how the combined pipeline is managed.

What Investors Should Watch

The main catalysts are procedural. The scheme requires approval by a majority in number of members voting at a court-convened scheme meeting, representing at least 75% in value, plus a special resolution backed by at least 75% of votes cast at a general meeting. Specific meeting dates were not confirmed, so investors may watch for the definitive proxy and scheme document. Regulatory conditions include expiry or early termination of the U.S. Hart-Scott-Rodino Waiting Period and German antitrust clearance, followed by sanction from the High Court of Justice of England and Wales. Absence of a company material adverse effect is another condition. Any news on how Merck intends to design divesiran's Phase 3 program could also draw attention, though such updates would come after closing.

Deal Mechanics Over Development Risk

Silence's story is now largely defined by deal mechanics rather than standalone development risk. The cash consideration is fixed, the expected closing window is the first quarter of 2027, and the remaining conditions are shareholder, antitrust and court approvals. Those steps are customary for a UK scheme, but each carries timing risk. For market participants, the progression of filings, votes and regulatory clearances over the coming months may be the clearest indicator of how the transaction is advancing.